Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Nondependent Opioid Abuse, Episodic
Interventions
DRUG

Placebo

Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage

DRUG

MS Contin (morphine sulfate, controlled release)

Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage

DRUG

EMBEDA (morphine sulfate / naltrexone hydrochloride)

Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage

Trial Locations (1)

84106

Lifetree Clinical Research, Salt Lake City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY